Gilead Sciences (NASDAQ:GILD) Trading 0.7% Higher

Gilead Sciences, Inc. (NASDAQ:GILD) shares were up 0.7% on Thursday . The company traded as high as $69.52 and last traded at $69.21. Approximately 2,191,498 shares were traded during trading, a decline of 71% from the average daily volume of 7,460,754 shares. The stock had previously closed at $68.75.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a report on Monday. TD Cowen decreased their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, April 26th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. Maxim Group lowered their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Finally, Oppenheimer reissued an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Twelve investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $84.00.

Gilead Sciences Trading Up 1.8 %

The firm has a market capitalization of $87.17 billion, a P/E ratio of 192.25, a PEG ratio of 2.87 and a beta of 0.18. The business’s 50 day moving average is $66.23 and its two-hundred day moving average is $71.88. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $1.37 EPS. Analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.40%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.29% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Public Sector Pension Investment Board raised its position in Gilead Sciences by 11.7% during the third quarter. Public Sector Pension Investment Board now owns 133,470 shares of the biopharmaceutical company’s stock valued at $10,002,000 after buying an additional 14,029 shares during the period. EP Wealth Advisors LLC increased its position in Gilead Sciences by 16.2% in the 3rd quarter. EP Wealth Advisors LLC now owns 47,110 shares of the biopharmaceutical company’s stock worth $3,530,000 after purchasing an additional 6,560 shares during the last quarter. Trust Co. of Vermont raised its stake in shares of Gilead Sciences by 16.0% during the 3rd quarter. Trust Co. of Vermont now owns 8,266 shares of the biopharmaceutical company’s stock worth $619,000 after purchasing an additional 1,139 shares in the last quarter. American Century Companies Inc. lifted its holdings in Gilead Sciences by 6.2% in the 3rd quarter. American Century Companies Inc. now owns 2,452,616 shares of the biopharmaceutical company’s stock worth $183,799,000 after purchasing an additional 143,570 shares during the last quarter. Finally, Hudson Bay Capital Management LP boosted its position in Gilead Sciences by 355.0% during the third quarter. Hudson Bay Capital Management LP now owns 247,500 shares of the biopharmaceutical company’s stock worth $18,548,000 after purchasing an additional 193,100 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.